A basic research breakthrough is improving patient lives, as researchers realized their rare genetic condition could be treated by repurposing a common anti-diabetic medication. The treatment has already been tested on several patients and has been a huge success with clinical trials now being initiated around the world.
With COVID-19 cases soaring into the millions, and a vaccine still a long way off, patients are desperate for a treatment. In response, numerous clinical trials have been initiated around the world. The majority of these trials are examining existing drugs to see if they can be repurposed to treat COVID-19. We spoke with Prof. Bart Lambrecht, pulmonologist at Ghent University Hospital (UZ Gent), about some of the clinical trials taking place here in Belgium.
Ghent (Belgium), 7 May 2020 - For the past five years, BioVox has provided a growing international community of readers with insights into the Belgian life sciences ecosystem. Our free monthly newsletter features exclusive content on the latest breakthroughs and industry developments. After half a decade of success, BioVox has now launched a fresh new website featuring Onno Van De Stolpe sharing his insights on the Belgian life sciences ecosystem.
Ghent, Belgium, April 2, 2020 - Biogazelle NV, a CRO specialized in RNA analytics, has announced the initiation of large-scale testing of patient samples for SARS-CoV-2. Biogazelle is providing one of the multiple testing sites in a government-led consortium of pharma, biotech, IT and academia, alongside Janssen Pharmaceutica (J&J), GSK, UCB, UgenTec, MIPS and ThermoFisher.
University Hospital Ghent and VIB are assessing a drug called Leukine® to treat patients with respiratory illness associated with COVID-19. Major medical centers in Germany and Italy are considering joining the study. The study will evaluate the effect of Leukine® on lung function and patient outcomes.
Mechelen, Belgium, 24 March 2020 - The coronavirus has brought the whole world to a standstill. The Belgian company ElmediX wants to contain the virus with intensive heat treatments for corona patients. Controlled heating to 41.5 °C for three hours can inactivate the virus and activate the patient's immune system. ElmediX has launched a call to researchers and doctors and makes the technology available in the fight against the coronavirus.
A basic research breakthrough is improving patient lives, as researchers realized their rare genetic condition could be treated by repurposing a common anti-diabetic medication. The treatment has already been tested on several patients and has been a huge success with clinical trials now being initiated around the world.
With COVID-19 cases soaring into the millions, and a vaccine still a long way off, patients are desperate for a treatment. In response, numerous clinical trials have been initiated around the world. The majority of these trials are examining existing drugs to see if they can be repurposed to treat COVID-19. We spoke with Prof. Bart Lambrecht, pulmonologist at Ghent University Hospital (UZ Gent), about some of the clinical trials taking place here in Belgium.
Ghent (Belgium), 7 May 2020 - For the past five years, BioVox has provided a growing international community of readers with insights into the Belgian life sciences ecosystem. Our free monthly newsletter features exclusive content on the latest breakthroughs and industry developments. After half a decade of success, BioVox has now launched a fresh new website featuring Onno Van De Stolpe sharing his insights on the Belgian life sciences ecosystem.
Ghent, Belgium, April 2, 2020 - Biogazelle NV, a CRO specialized in RNA analytics, has announced the initiation of large-scale testing of patient samples for SARS-CoV-2. Biogazelle is providing one of the multiple testing sites in a government-led consortium of pharma, biotech, IT and academia, alongside Janssen Pharmaceutica (J&J), GSK, UCB, UgenTec, MIPS and ThermoFisher.
University Hospital Ghent and VIB are assessing a drug called Leukine® to treat patients with respiratory illness associated with COVID-19. Major medical centers in Germany and Italy are considering joining the study. The study will evaluate the effect of Leukine® on lung function and patient outcomes.
Mechelen, Belgium, 24 March 2020 - The coronavirus has brought the whole world to a standstill. The Belgian company ElmediX wants to contain the virus with intensive heat treatments for corona patients. Controlled heating to 41.5 °C for three hours can inactivate the virus and activate the patient's immune system. ElmediX has launched a call to researchers and doctors and makes the technology available in the fight against the coronavirus.